Flood of new cancer drug data presented at ASCO; nearly 1,000 being tested

4 June 2012

The annual prestigious American Society of Clinical Oncology (ASCO) meeting taking place in Chicago, as usual, saw a plethora of new data on cancer drugs under development by the pharmaceutical and biotechnology industry, some of which are highlighted below.

The meeting kicked off just after trade group Pharmaceutical Research and Manufacturers of America issued a new report showing that the USA’s biopharmaceutical research companies are testing 981 medicines and vaccines to fight the many types of cancer affecting millions of patients worldwide. These potential medicines, which are either in clinical trials or under review by the Food and Drug Administration, include 121 for lung cancer, 117 for lymphoma and 111 for breast cancer. The full report is available on PhRMA’s web site.

Roche “armed antibody” delays breast tumor growth

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK